Ambrx Biopharma to Host Corporate Update Conference Call

Rhea-AI Summary

Ambrx Biopharma Inc. (AMAM) will host a corporate update conference call and webcast on October 18, 2022, at 2:00 p.m. PT to discuss outcomes from its strategic review initiated in August 2022. The company focuses on developing Engineered Precision Biologics through its expanded genetic code technology. Interested participants can register via the investor relations section of www.ambrx.com. A replay will be available for 90 days post-call.

Conference call to discuss outcome of the strategic review that was initiated in August 2022

SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company’s strategic review of its development pipeline.

Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company’s website at: www.ambrx.com.

To access the call by phone, please use the registration link on the investor relations section of the website, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A webcast replay will be available in the investor relations section of the company’s website for 90 days following the completion of the call.

About Ambrx Biopharma Inc. (Ambrx)

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com.

Contacts

INVESTORS
Laurence Watts
Managing Director
Gilmartin Group, LLC.
619-916-7620
ir@ambrx.com

MEDIA
media@ambrx.com

Source: Ambrx, Inc.

FAQ

What is the date and time of Ambrx's conference call regarding the strategic review?

The conference call will take place on October 18, 2022, at 2:00 p.m. Pacific Time.

How can I access the Ambrx conference call?

Participants can access the call via the registration link on the investor relations section of Ambrx's website.

What will be discussed in the Ambrx conference call?

The conference call will discuss the outcomes of the strategic review of Ambrx's development pipeline.

Where can I find a replay of the Ambrx conference call?

A replay of the conference call will be available on Ambrx's investor relations website for 90 days after the event.

What technology does Ambrx use for its Engineered Precision Biologics?

Ambrx uses an expanded genetic code technology platform to develop its Engineered Precision Biologics.